|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.125 USD | -2.47% |
|
-2.96% | -31.01% |
| 05-07 | Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026 | |
| 05-06 | Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026 | CI |
Business description: Vanda Pharmaceuticals Inc.
Number of employees: 533
Sales by Activity: Vanda Pharmaceuticals Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | 269M | 254M | 193M | 199M | 216M |
Geographical breakdown of sales: Vanda Pharmaceuticals Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 269M | 254M | 193M | 199M | 216M |
Executive Committee: Vanda Pharmaceuticals Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 30/04/2003 | |
Kevin Moran
DFI | Director of Finance/CFO | 42 | 14/03/2020 |
Scott Howell
HRO | Human Resources Officer | - | 31/07/2019 |
Kim Wijkstrom
SAM | Sales & Marketing | 60 | 20/08/2019 |
| Corporate Officer/Principal | 57 | 31/05/2003 |
Composition of the Board of Directors: Vanda Pharmaceuticals Inc.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 31/05/2021 | |
Richard Dugan
BRD | Director/Board Member | 84 | 30/11/2005 |
Phaedra Chrousos
BRD | Director/Board Member | 46 | 23/04/2019 |
Anne Ward
BRD | Director/Board Member | 54 | 27/10/2019 |
Stephen Mitchell
BRD | Director/Board Member | 74 | 13/02/2020 |
Tage Honoré
BRD | Director/Board Member | 75 | 14/03/2023 |
Charles Duncan
BRD | Director/Board Member | - | 21/04/2026 |
Company details: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
20037, Washington
+202 734 3400
http://www.vandapharma.com
Bio Therapeutic Drugs
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.47% | -2.96% | +41.17% | -0.42% | 378M | |
| -2.54% | -2.26% | +33.25% | +75.07% | 50.1B | |
| -1.05% | -4.45% | +66.31% | +50.52% | 45.82B | |
| -2.00% | +3.28% | +58.07% | +470.14% | 23.66B | |
| -1.20% | -5.51% | -9.82% | -15.96% | 22.65B | |
| -2.20% | +0.86% | +39.87% | -26.56% | 17.8B | |
| +0.39% | +1.90% | +28.07% | -41.95% | 16.08B | |
| -5.32% | -15.07% | +36.29% | +202.26% | 14.14B | |
| -5.90% | -15.27% | -34.15% | +875.92% | 13.09B | |
| -2.84% | -5.14% | +32.07% | - | 13B | |
| Average | -2.56% | -2.24% | +29.11% | +176.56% | 21.67B | |
| Weighted average by Cap. | -2.23% | -1.80% | +34.68% | +147.36% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VNDA Stock
- Company Vanda Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition